State of Alaska Department of Revenue Has $25.78 Million Stake in Pfizer Inc. (NYSE:PFE)

State of Alaska Department of Revenue decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 895,381 shares of the biopharmaceutical company’s stock after selling 56,605 shares during the period. State of Alaska Department of Revenue’s holdings in Pfizer were worth $25,777,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. RB Capital Management LLC grew its holdings in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. grew its holdings in Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the period. United Bank boosted its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC boosted its position in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Barclays lowered their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, UBS Group decreased their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.03 on Friday, reaching $27.75. 40,466,657 shares of the stock were exchanged, compared to its average volume of 47,662,984. The firm’s 50 day moving average is $27.45 and its 200-day moving average is $29.45. Pfizer Inc. has a one year low of $25.61 and a one year high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.